Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Expands Investment Banking Platform with Acquisition of Armentum Partners

    William Blair today announced it has acquired Armentum Partners, a premier boutique debt and alternative capital solutions advisory firm serving venture-backed businesses, public companies, and academic institutions.

    Read more

  • William Blair Investment Management Completes Conversion of Emerging Markets Fixed Income Mutual Fund to Active ETF

    William Blair Investment Management today announced it has completed the conversion of the William Blair Emerging Markets Debt Mutual Fund into a new actively managed exchange-traded fund, the William Blair Emerging Income ETF (WINC).

    Read more

  • Economics Weekly: Where Have All the Foreign Profits Gone

    In this Economics Weekly, Richard de Chazal examines what has changed, why the foreign share of U.S. corporate profits has collapsed, and what that means for investors.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures